Fraunhofer Strasse 13, 4th Floor
iOmx is a dynamic biotech company developing novel immuno-oncology drugs. The Company is well financed by an international consortium of leading life science investors. iOmx focuses on innovation-driven research to advance its proprietary early-stage novel immune-checkpoint molecules through pre-clinical and clinical development.
Co-Founder and CEO: David S. Joseph
CMO: Elizabeth A. Perkett
Chief Science Advisor: Graham S. Timmins, PH.D.
Senior Vice President, Product Development: David Karshmer
Vice President, Product Management: John Maynard
Vice President, Finance: Matt Culler
Please click here for iOmx job opportunities.
Please click here for iOmx's pipeline.